HR Business Partner - (South San Francisco, CA)

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a world-class management team with significant background in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy applicants with the goal of delivering readily available cell therapy faster, more reliably and at greater scale to more patients. AlloCAR T™ cell therapies are engineered from cells of healthy donors, which is intended to allow for creation of inventory for on demand use in patients. This approach is designed to eliminate the need to create personalized therapy from a patient’s own cells, simplify manufacturing, and reduce the time patients must wait for CAR T cell treatment.